Morphiex is harnessing the power of the immune system to fight cancer by developing the only dual-functioning #CD47 immune checkpoint inhibitor. Our lead drug candidate, MBT-001, blocks both "don't eat me" and thrombospondin-1 (TSP-1) pathways of #CD47. This enables direct tumor cell killing mediated by T cells, Natural Killer cells, Neutrophils as well as Macrophages.
MBT-001 was developed at the National Cancer Institute (NCI) at the National Institutes of Health (NIH) and is exclusively licensed to Morphiex for the treatment of cancer as a monotherapy or in combination with other modalities such as chemotherapy, immune checkpoint inhibitors, CAR-T and many others. Morphiex has entered into a cooperative research and development agreement (CRADA) with the NIH/NCI to accelerate the development of MBT-001.
Company Details
- Founded
- 2018
- Address
- 240 Newbury Street, 2nd Floor, Boston,massachusetts 02116,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.morphiex.com
- Keywords
- oncology, CD47, immune-checkpoint.
- HQ
- Boston, Massachusetts
Morphiex Biotherapeutics Questions
Morphiex Biotherapeutics's website is http://www.morphiex.com
Morphiex Biotherapeutics's LinkedIn profile is https://www.linkedin.com/company/morphiex
Morphiex Biotherapeutics's industry is
Biotechnology Research
Morphiex Biotherapeutics's top competitors are
Matrix Bio,
Biovisors Consulting,
Primera Therapeutics,
Tessera Therapeutics,
Abvance Therapeutics,
Keryx Pharmaceuticals Pvt Ltd,
Hibiscus Bioventures,
Regio Biosciences,
Artan Bio,
Reverie Labs.
Morphiex Biotherapeutics's categories are Biotechnology Research
Morphiex Biotherapeutics's founding year is 2018
